Press release
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) –\n\n\n− Company Provides 2026 Combined Net Product Revenue Guidance of $4,900 Million to $5,300 Million, Driven Primarily by Total TTR Net Product Revenue Guidance of $4,400 Million to $4,700 Million –\n\n\n– 2026 Pipeline Goals Focused on Continued Advancement of Numerous Multi-Billion-Dollar Opportunities –\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO.\n\n\nNew Five-Year Strategy: Alnylam 2030\n\n\nAlnylam 2030 continues the Company’s 15-year heritage of establishing and delivering on ambitious five-year goals, the most recent of which was Alnylam P5x25. Over that time period, Alnylam has either met or exceeded all of its prior five-year goals.\n\n\nAlnylam 2030 is focused on continuing to successfully scale the Company’s operations. Specifically, the Company intends to achieve the following by the end of 2030:\n\n\n\nAchieve Global TTR Leadership: Build a Durable TTR Franchise\n\n\nLead TTR market in revenue by 2030 and cumulatively across five-year period\n\n\n\nLaunch best-in-class, next-gen silencer, nucresiran, in polyneuropathy by 2028 and cardiomyopathy by 2030\n\n\n\n\n\n\n\nGrow Through Sustainable Innovation: Deliver Therapies that Prevent, Halt, or Reverse Disease\n\n\nDeliver 2+ new transformative medicines beyond TTR with blockbuster potential\n\n\n\nExpand to 10 tissue types and >40 clinical programs\n\n\n\nInvest ~30% of revenues in non-GAAP R&D, including select external innovation\n\n\n\n\n\n\n\nScale with Discipline & Agility: Drive Sustained, Profitable Growth\n\n\nAchieve 25%+ total revenue CAGR through year-end 2030\n\n\n\nDeliver ~30% non-GAAP operating margin\n\n\n\n\n\n\n“The past five years have been transformati...